Drug that lowers blood sugar to combat type 2 diabetes ‘also helps fight obesity and heart disease’
A DRUG used to treat diabetes has been hailed a game changer after experts found it not only slashes blood sugar levels but can also protect against heart and kidney disease.
The drug, taken once a day, lowers blood pressure and combats obesity, one of the main causes of type 2 diabetes, a new study shows.
Canagliflozin, sold under trade name Invokana, reduces the overall risk of heart disease by 14 per cent and slashed the risk of hospitalisation for heart failure by 33 per cent.
And researchers from The George Institute for Global Health, found it also had a "significant impact" on the progression of kidney disease.
Professor Bruce Neal described the findings as "exciting", adding they offer real hope to people with type 2 diabetes.
He said: "Coronary heart disease is the biggest killer by far for people with type 2 diabetes.
"Our findings suggest that not only does canagliflozin significantly reduce the risk of heart disease, it also has many other benefits too.
"We found it also reduced blood pressure and led to weight loss.
"Type 2 diabetes is growing rapidly all over the world and we need drugs that not only deal with glucose levels, but that also protect the many millions of people from the very real risks of stroke and heart attack."
Invokana is known as a SGLT2 inhibitor and is a relatively new drug, that works to block the body's reabsorption of sugar or glucose.
It is already available to patients in the UK, prescribed by doctors to help manage type 2 diabetes.
The National Institute for Health and Care Excellence (Nice) stated in 2014 canagliflozin Continue reading